Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)

Completed · Phase 3 · Has a placebo group

Conditions studied: Type 2 Spinal Muscular Atrophy

In brief

This was a Phase III multi-center, single dose (1.2 x 10\^14 vector genomes), randomized, sham controlled, double-blind study that investigates the efficacy, safety and tolerability of OAV101B in treatment naive, sitting and never ambulatory SMA patients 2 to \<18 years of age.

Key facts

Study ID
NCT05089656
Run by
Novartis Pharmaceuticals
People needed
126
Starts
2022-02-01
Expected to finish
2025-04-29
Last updated by the study team
2026-01-13

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.